Trump Administration set to demonstrate point-of-care technology to help prevent IV fluid shortages
Two locations selected to demonstrate Caspian, an automated, point-of-care, sterile saline manufacturing system that may help prevent or mitigate intravenous (IV) fluid shortages in the United States. The post Trump Administration set to demonstrate point-of-care technology to help prevent IV fluid shortages appeared first on MedTech Intelligence.
WASHINGTON, DC, June 5, 2025 (ASPR Newsroom) – The U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response (ASPR) today announced two locations selected to demonstrate Caspian, an automated, point-of-care, sterile saline manufacturing system that may help prevent or mitigate intravenous (IV) fluid shortages in the United States.
Caspian’s development was initiated in 2019 in response to President Trump’s leadership in efforts to address persistent medical supply chain disruptions, and supports the President’s Executive Order: Regulatory Relief to Promote Domestic Production of Critical Medicines.
“Despite being one of the most commonly used supportive care solutions in patient care, IV fluids have been in shortage since 2018,” said John Knox, Principal Deputy Assistant Secretary for the Administration for Strategic Preparedness and Response. “Under President Trump’s leadership, we are helping to ensure that patients don’t have their medical care delayed or cancelled due to shortages of IV fluids by manufacturing them here at home through Caspian.”
On-demand, on-site production technology is critical to our efforts to reshore American manufacturing, secure domestic supply chains, and reduce U.S. dependence on foreign nations for critical medicines and therapies.
Caspian is being developed by DEKA Research and Development Corp. in Manchester, New Hampshire, with ASPR support. One Caspian unit will be delivered to Walter Reed Medical Center in Bethesda, Maryland, where it aims to demonstrate how the saline-on-demand system can help meet patients’ needs in medical facilities, and the other unit will be delivered to the U.S. Food & Drug Administration for additional review.
In preparation for delivery to these locations in the Fall of 2025, ASPR is working with DEKA to complete the final steps in producing the units with the intent to produce up to 500 bags of IV fluid each day.
Automated, integrated quality controls in each Caspian unit are connected to a cloud-based quality manager to ensure all the final IV products meet all quality specifications.
The post Trump Administration set to demonstrate point-of-care technology to help prevent IV fluid shortages appeared first on MedTech Intelligence.
